Raphael Allgaier, Arne Kandulski, Karsten Gülow, Lars Maier, Martina Müller, Hauke Christian Tews
{"title":"病例报告:单次给药后同时诱导中性粒细胞减少和溶血。","authors":"Raphael Allgaier, Arne Kandulski, Karsten Gülow, Lars Maier, Martina Müller, Hauke Christian Tews","doi":"10.1007/s40268-023-00415-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Metamizole is a non-opioid ampyrone sulfonate compound with potent analgesic, antipyretic, and spasmolytic effects. Agranulocytosis is a rare life-threatening complication of metamizole.</p><p><strong>Case: </strong>Here, we present the case of a 62-year-old patient who developed agranulocytosis as well as hemolysis after a single administration of metamizole.</p><p><strong>Conclusion: </strong>This case illustrates the inherent allergic potential of metamizole and its effects on different hematopoietic cell types.</p>","PeriodicalId":49258,"journal":{"name":"Drugs in Research & Development","volume":"23 2","pages":"93-98"},"PeriodicalIF":2.2000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/47/97/40268_2023_Article_415.PMC10293139.pdf","citationCount":"1","resultStr":"{\"title\":\"Case Report: Simultaneously Induced Neutropenia and Hemolysis After a Single Metamizole Dose.\",\"authors\":\"Raphael Allgaier, Arne Kandulski, Karsten Gülow, Lars Maier, Martina Müller, Hauke Christian Tews\",\"doi\":\"10.1007/s40268-023-00415-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objective: </strong>Metamizole is a non-opioid ampyrone sulfonate compound with potent analgesic, antipyretic, and spasmolytic effects. Agranulocytosis is a rare life-threatening complication of metamizole.</p><p><strong>Case: </strong>Here, we present the case of a 62-year-old patient who developed agranulocytosis as well as hemolysis after a single administration of metamizole.</p><p><strong>Conclusion: </strong>This case illustrates the inherent allergic potential of metamizole and its effects on different hematopoietic cell types.</p>\",\"PeriodicalId\":49258,\"journal\":{\"name\":\"Drugs in Research & Development\",\"volume\":\"23 2\",\"pages\":\"93-98\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/47/97/40268_2023_Article_415.PMC10293139.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs in Research & Development\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40268-023-00415-9\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Research & Development","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40268-023-00415-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Case Report: Simultaneously Induced Neutropenia and Hemolysis After a Single Metamizole Dose.
Background and objective: Metamizole is a non-opioid ampyrone sulfonate compound with potent analgesic, antipyretic, and spasmolytic effects. Agranulocytosis is a rare life-threatening complication of metamizole.
Case: Here, we present the case of a 62-year-old patient who developed agranulocytosis as well as hemolysis after a single administration of metamizole.
Conclusion: This case illustrates the inherent allergic potential of metamizole and its effects on different hematopoietic cell types.
期刊介绍:
Drugs in R&D is an international, peer reviewed, open access, online only journal, and provides timely information from all phases of drug research and development that will inform clinical practice. Healthcare decision makers are thus provided with knowledge about the developing place of a drug in therapy.
The Journal includes:
Clinical research on new and established drugs;
Preclinical research of direct relevance to clinical drug development;
Short communications and case study reports that meet the above criteria will also be considered;
Reviews may also be considered.